Search Results - "Ammann, Johannes"

Butyrophilin Btn2a2 inhibits TCR activation and phosphatidylinositol 3-kinase/Akt pathway signaling and induces Foxp3 expression in T lymphocytes by Ammann, Johannes U, Cooke, Anne, Trowsdale, John

“…The butyrophilin-related protein Btn2a2 was upregulated on murine APC including CD19(+) B cells, CD11b(+)F4/80(+) peritoneal macrophages, and CD11c(+) bone…”
Get full text

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays by Schwamborn, Kristina, Ammann, Johannes U, Knüchel, Ruth, Hartmann, Arndt, Baretton, Gustavo, Lasitschka, Felix, Schirmacher, Peter, Braunschweig, Till, Tauber, Robert, Erlmeier, Franziska, Hieke-Schulz, Stefanie, Weichert, Wilko

“…Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) correlated in several studies with PD-L1/programmed…”
Get full text

A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer by Noske, Aurelia, Ammann, Johannes U, Wagner, Daniel‐Christoph, Denkert, Carsten, Lebeau, Annette, Sinn, Peter, Kreipe, Hans‐Heinrich, Sommer, Ulrich, Baretton, Gustavo, Steiger, Katja, Kiechle, Marion, Hieke‐Schulz, Stefanie, Flores, Mike, Roth, Wilfried, Weichert, Wilko

“…Aims Studies in various cancer types have demonstrated discordance between results from different programmed death‐ligand 1 (PD‐L1) assays. Here, we compare…”
Get full text

BTN1A1, the Mammary Gland Butyrophilin, and BTN2A2 Are Both Inhibitors of T Cell Activation by Smith, Isobel A, Knezevic, Brittany R, Ammann, Johannes U, Rhodes, David A, Aw, Danielle, Palmer, Donald B, Mather, Ian H, Trowsdale, John

“…Butyrophilin (BTN) genes encode a set of related proteins. Studies in mice have shown that one of these, BTN1A1, is required for milk lipid secretion in…”
Get full text

Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA) by Iivanainen, Sanna, Baird, Anne-Marie, Balas, Bogdana, Bustillos, Alberto, Castro Sanchez, Amparo Yovanna, Eicher, Manuela, Golding, Sophie, Mueller-Ohldach, Mathis, Reig, Maria, Welslau, Manfred, Ammann, Johannes

“…IntroductionDigital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad…”
Get full text

Evolving regulatory perspectives on digital health technologies for medicinal product development by Colloud, Seya, Metcalfe, Thomas, Askin, Scott, Belachew, Shibeshih, Ammann, Johannes, Bos, Ernst, Kilchenmann, Timothy, Strijbos, Paul, Eggenspieler, Damien, Servais, Laurent, Garay, Chloé, Konstantakopoulos, Athanasios, Ritzhaupt, Armin, Vetter, Thorsten, Vincenzi, Claudia, Cerreta, Francesca

“…Digital health technology tools (DHTTs) present real opportunities for accelerating innovation, improving patient care, reducing clinical trial duration and…”
Get full text

Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-KB inhibition by AMMANN, Johannes U, HAAG, Christian, KASPERCZYK, Hubert, DEBATIN, Klaus-Michael, FULDA, Simone

Get full text

Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany by Rüschoff, Josef, Lebeau, Annette, Sinn, Peter, Schildhaus, Hans-Ulrich, Decker, Thomas, Ammann, Johannes, Künzel, Claudia, Koch, Winfried, Untch, Michael

“…The German NIU HER2 model was developed based on five variables found to have statistically significant influences on HER2-positivity, to allow exploration of…”
Get full text

Detection of weak receptor–ligand interactions using IgM and J‐chain‐based fusion proteins by Ammann, Johannes U., Jahnke, Martin, Dyson, Michael R., Kaufman, Jim, Trowsdale, John

Get full text

Development and use of IgM/J-chain fusion proteins for characterization of immunoglobulin superfamily ligand-receptor interactions by Ammann, Johannes U, Trowsdale, John

“…Discovery of binding partners for immunoglobulin molecules expressed by cells of the immune system is an important topic of current research. However, many…”
Get more information

Use and value of self-management (SM) recommendations in a real-world evidence study evaluating digital patient monitoring (DPM) of patients (pts) receiving cancer care by Eicher, Manuela, Bana, Marika, Ribi, Karin, Schneider, Sophie, Ammann, Johannes

“…1603 Background: SM includes pts’ abilities and activities to manage symptoms, treatment (tx), and any problems inherent to a chronic condition. Tailored SM…”
Get full text

Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients by Schmalz, Oliver, Jacob, Christine, Ammann, Johannes, Liss, Blasius, Iivanainen, Sanna, Kammermann, Manuel, Koivunen, Jussi, Klein, Alexander, Popescu, Razvan Andrei

“…Cancer immunotherapy (CIT), as a monotherapy or in combination with chemotherapy, has been shown to extend overall survival in patients with locally advanced…”
Get full text

Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer by Arriola, Edurne, Jaal, Jana, Edvardsen, Anne, Silvoniemi, Maria, Araújo, António, Vikström, Anders, Zairi, Eleni, Rodriguez-Mues, Mari Carmen, Roccato, Marco, Schneider, Sophie, Ammann, Johannes

“…Digital patient monitoring (DPM) tools can facilitate early symptom management for patients with cancer through systematic symptom reporting; however, low…”
Get full text

An interventional study of the impact of digital patient monitoring (DPM) on health outcomes, healthcare resource utilization, and feasibility of a combination with at-home treatment (tx) for delivery of systemic anticancer tx in clinical practice by Iivanainen, Sanna, Baird, Anne-Marie, Balas, Bogdana, Bustillos, Alberto, Castro, Yovanna, Eicher, Manuela, Golding, Sophie, Mueller-Ohldach, Mathis, Reig, Maria, Welslau, Manfred, Ammann, Johannes

“…TPS1617 Background: Disease- and tx-related symptoms negatively affect quality of life and may become life-threatening. There is a need for improved…”
Get full text

Real-world implementation and user experience of tailored digital patient monitoring (DPM) modules for patients (pts) with locally advanced/metastatic (LA/M) cancer: Early readout analysis from a feasibility study by Jaal, Jana, Arriola, Edurne, Rodriguez-Mues, Mari Carmen, Edvardsen, Anne, Silvoniemi, Maria, Vettus, Elen, Zairi, Eleni, Roccato, Marco, Schneider, Sophie, Ammann, Johannes

“…e13608 Background: Poor control of disease- and treatment-related symptoms can impact negatively on quality of life and clinical outcomes in pts with cancer…”
Get full text

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany by Rüschoff, Josef, Lebeau, Annette, Kreipe, Hans, Sinn, Peter, Gerharz, Claus Dieter, Koch, Winfried, Morris, Stefanie, Ammann, Johannes, Untch, Michael

“…Despite >10 years of routine human epidermal growth factor receptor 2 (HER2) testing in breast cancer, testing quality is still an issue. Guidelines recommend…”
Get full text

Butyrophilin Btn2a2 inhibits T cell receptor activation, PI3K/Akt pathway signaling, and induces Foxp3 expression in T lymphocytes by Ammann, Johannes U, Cooke, Anne, Trowsdale, John

“…The butyrophilin-related protein Btn2a2 was up-regulated on murine antigen presenting cells including CD19+ B cells, CD11b+ F4/80+ peritoneal macrophages, and…”
Get full text

Abstract 4037: Analytical and inter-observer comparability of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry assays in advanced clear cell renal cell carcinoma (CCRCC) by Sommer, Ulrich, Eckstein, Markus, Ammann, Johannes, Braunschweig, Till, Macher-Goeppinger, Stephan, Schwamborn, Kristina, Hieke-Schulz, Stefanie, Wullich, Bernd, Wirth, Manfred, Roth, Wilfried, Knüchel, Ruth, Weichert, Wilko, Baretton, Gustavo, Hartmann, Arndt

“…Abstract Background: PD-L1/programmed cell death-1 (PD-1)-targeting checkpoint inhibitors have shown clinical activity in advanced and metastatic RCC, which…”
Get full text

Sensitization of neuroblastoma cells for TRAIL‐induced apoptosis by NF‐κB inhibition by Ammann, Johannes U., Haag, Christian, Kasperczyk, Hubert, Debatin, Klaus‐Michael, Fulda, Simone

“…The transcription factor nuclear factor‐kappaB (NF‐κB) plays a central role in stress‐induced transcriptional activation and has been implicated in…”
Get full text

Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma by Sommer, Ulrich, Eckstein, Markus, Ammann, Johannes, Braunschweig, Till, Macher-Göppinger, Stephan, Schwamborn, Kristina, Hieke-Schulz, Stefanie, Harlow, Greg, Flores, Mike, Wullich, Bernd, Wirth, Manfred, Roth, Wilfried, Knüchel, Ruth, Weichert, Wilko, Baretton, Gustavo, Hartmann, Arndt

“…Previous studies have suggested increased clinical benefit with inhibition of programmed death-ligand 1 (PD-L1)/programmed death-1 in patients with…”
Get full text